This article contains an analysis of a proper distribution of rights between the interest of patients giving their biological data within a clinical trial scenario and the researchers producing results out of these data taking as case of study the EU funded project Advancing Clinico Genomic Trial on Cancer (ACGT). It includes an analysis of the unfair distribution of rights in the Moore and Greenberg cases in the US followed by seven different models to balance these rights within a clinical trial scenario aiming at finding the best equilibrium between patients and researchers.